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Eosinophilia is indicative of a humoral immune response. Under
conditions of poverty, this kind of profile is often the result of
sustained contact with helminthic antigens; whereas antigens
that give rise to atopy may be the main cause under conditions of
affluence. Infestation of humans by various parasitic helminths
is widespread in South Africa.1–4 The epidemiological and public
health importance of helminth-induced eosinophilia includes
the possibility that underlying chronic immune activation
creates the potential for interaction with co-endemic diseases
and preventive vaccination.5–26 When pregnant women are
parasitized by worms in Africa, and probably elsewhere as well,
even the foetus becomes sensitized to helminths, and the T-cell
priming persists into childhood.23 This perinatal T-cell imbalance
could influence susceptibility to infection by intracellular
pathogens, efficacy of vaccines, and development of immune-
mediated disorders.5–26 The purpose of this paper is to describe
deworming interventions at two South African schools, during
which significant reductions in mean eosinophil counts, and
reductions in the prevalence of eosinophilia, were sustained;
and to consider briefly the implications in the context of co-
endemic human helminthiasis, other infections, and allergies.
Methods
The effects on eosinophilia of the anthelminthics, albendazole
and mebendazole, were determined during a randomized
controlled trial and a whole-school deworming programme.
Free and informed consent to treat the children with anthel-
minthic tablets as the only medication, and to draw blood from
them, was obtained from all parents or guardians, and from the
school committees. Both of the projects were approved by the
Ethics Committee of the South African Medical Research Council.
Randomized controlled trial
The original objective was to benchmark the efficacy of
albendazole (Zentel® 400 mg tablets, SmithKline Beecham)
against the whipworm Trichuris trichiura in the Mediterranean-
type climate (winter rainfall area) of the Western Cape Province
of South Africa, in terms of cure rate and egg reduction rate.27
The participants (n = 155) were children of wine-farm labourers,
attending a primary school in the Boland region,100 km east of
Cape Town. Median age at commencement was 112 months
(range 78–174 months). Albendazole doses of 400, 800 or 1200 mg
were each administered four times at intervals of approximately
four months. The main inclusion criterion for treatment with
albendazole was the presence of Trichuris eggs in a faecal sample,
resulting in a prevalence of 100% in three groups matched for
age, gender and the number of Trichuris eggs per gram of stool.
Allocation of a group of children to a particular dose of
albendazole was by a randomized process. Concomitant infec-
tion with the common roundworm Ascaris lumbricoides occurred
in 47%, 50%, 54% and 0% of children who received 400, 800 or
1200 mg of albendazole, or placebo, respectively.27 There was an
ethical directive that children known to have worms must not be
treated with placebo. Therefore, individuals with no eggs in
their faeces when the study commenced were dosed with
placebo tablets and served as a negative control (or reference)
group. Appearance and flavour of albendazole and placebo
tablets matched exactly, and each tablet was blister-packed in
France. Sets of three packs of albendazole and/or placebo for
treatments spanning three days at 400 mg/day, were prepared in
the laboratory. At the school, administration of each set to the
corresponding child was double blind. Before deworming
started and after two and four deworming treatments, blood
was drawn from the antecubital vein into vacuum tubes contain-
ing EDTA. Differential white blood cell counts were obtained by
means of a Technicon H2 blood cell analyser (Technicon,
Tarrytown, New York). Counts that exceeded normal ranges
were checked by microscopy. The laboratory reported results in
relation to the date of birth, but had no other specific knowledge
of the case. Repeated-measures analysis of variance was the
statistical method used to test eosinophil counts for dose effects,
and for interactions with time, age and gender. Counts were
made in all seasons of the year.27
Whole-school deworming programme
A community on the west coast, 135 km north of Cape Town,
requested assistance with implementation of a deworming
programme in their primary school.1 Intervention was
recommended after it had been shown that 72% of children
were infected by Trichuris and 19% with Ascaris. The schedule
was to deworm all the children at intervals of approximately
four months with a dose of one 500 mg mebendazole tablet per os
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Eosinophil counts in venous blood were monitored during a
randomized controlled deworming trial (n = 155 children) that
lasted for a year, and in a whole-school deworming programme
(range 174–256 children) of 2 years’ duration. Mean eosinophil
counts (×109/l) decreased from 0.70 in the randomized trial, and
0.61 in the whole-school study, to well within the normal paediatric
range of 0.05–0.45 (P < 0.05). The prevalence of eosinophilia
declined from 57% to 37% in the randomized trial (mean for 400, 800
and 1200 mg albendazole doses); and from 47% to 24% in the
whole-school study (500 mg stat mebendazole). Benzimidazole
anthelminthics were highly effective against Ascaris but less so
against Trichuris. Activated eosinophils are effector and immuno-
regulatory leucocytes of the T-helper cell type 2 (Th2) immune re-
sponse to parasitic helminths and atopic disorders. Under
conditions of poverty where soil-transmitted helminths are
hyperendemic, Th2 polarization of the immune profile is character-
istic. Regular anthelminthic treatment should reduce contact with
worm antigens, and this may contribute to re-balancing of the
immune profile. Suppression of eosinophil recruitment and activa-
tion, together with related cellular and molecular immunological
changes, might have positive implications for prevention and
treatment of co-endemic diseases, including HIV/AIDS, cholera,
tuberculosis and atopic disorders.
(Vermox®, Janssen-Cilag). Median age at commencement
was 111 months (range 46–218 months). Children were
dewormed six times. The number of children available for
venipuncture on different occasions ranged from 174–256,
depending on absenteeism and voluntary participation. Blood
cells were counted in the same laboratory and by the same
methods as for the randomized controlled trial. Differential
white blood cell counts defining eosinophilia were done before
and after two, four and six dewormings, respectively, utilizing
all children who presented for venipuncture. Changes in
eosinophil counts were evaluated statistically by repeated-mea-
sures analysis of variance. Counts were made in all seasons of
the year.
Results
The normal paediatric range for eosinophil counts at the
tertiary hospital (Tygerberg Hospital) serving both the study
populations is 0.05–0.45 × 109/l.28,29
Randomized controlled trial
Children who left the school, reduced numbers from the
original allocation of 25 boys and 25 girls per treatment
(Table 1).27 Compliance by ingestion of anthelminthic tablets was
100% in pupils who completed the study. The mean eosinophil
count exceeded the upper limit of the normal paediatric range
(0.45 × 109/l)28,29 before treatment with albendazole began
(Table 1). Sustained reductions in mean eosinophil counts were
statistically significant after two and four dewormings, and were
accompanied by reductions in the prevalence of eosinophilia,
for all the doses of albendazole. There was no clear dose-related
response but the 800 mg treatment was associated with the
largest reduction in counts (Table 1). There was a trend for
higher counts to decrease more in all the groups treated with
albendazole, in which prevalence of helminthiasis was
originally 100%. In these groups, but not in the placebo group,
the mean counts for successive ascending quartiles declined
from before treatment by 0%, 6%, 40% and 57% per quartile,
after four treatments. Eosinophilia was associated with
helminthiasis per se, rather than differentially with the severity
of either trichuriasis or ascariasis, or with concomitant infections
by both helminths (data not shown). There were no significant
interactions with gender, age or time. By the end of the study,
incidences per annum of 15% trichuriasis and 29% ascariasis in
the originally uninfected negative control group (treated with
placebo), were associated with increased mean eosinophil
counts and the prevalence of eosinophilia. Other leucocyte
counts were not influenced by the treatments. All the doses of
albendazole were highly effective, according to international
criteria,30 against Ascaris in terms of cure rates and egg reduction
rates; whereas only the 800 and 1200 mg doses were effective
against Trichuris (data not shown).
Whole-school deworming programme
Before deworming, the mean eosinophil count for the whole
school exceeded the upper limit of the normal paediatric range,
namely, 0.45 × 109/l (Table 2).28,29 Treatment compliance ranged
from 73% to 100% (mean 91.2%) and results are summarized in
Table 2. During the deworming programme, there were
sustained reductions in mean eosinophil counts and the preva-
lence of eosinophilia. Decreases in counts were significant after
two and four dewormings, and approached significance be-
tween the fourth and sixth treatments. Despite the constraints of
study design, there was again an implied trend for higher counts
to respond more to deworming. This was shown by reduction in
the mean counts for successive ascending quartiles from before
treatment, by 0%, 24%, 44% and 56% per quartile, after six treat-
ments. Again, eosinophilia was associated with helminthiasis per
se, rather than differentially with the intensity of either
trichuriasis or ascariasis, or with concomitant infections by both
helminths (data not shown). Other leucocyte counts were not
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Table 1. Changes in mean eosinophil counts and prevalence of eosinophilia in children: randomized controlled trial (worm prevalence before and after deworming is
summarized in the first footnote).
Before deworming After 2 dewormingsa After 4 dewormingsa
Treatment and number of children Meansa % > Means % > Means % >
(s.e.m.)b 0.45c (s.e.m.)b 0.45c (s.e.m.)b 0.45c
400 mgd (n = 37) 0.676 (0.087) 51 0.382 (0.035) 35 0.397 (0.037) 35
800 mgd n = 41) 0.762 (0.080) 66 0.548 (0.063) 49 0.426 (0.038) 41
1200 mgd (n = 40) 0.643 (0.075) 50 0.401 (0.071) 33 0.459 (0.061) 38
Referencee (n = 37) 0.384 (0.037) 29 0.342 (0.031) 27 0.472 (0.046) 49
Worm prevalence before and following deworming with albendazole: Trichuris 100% before and afterwards ranged from 33.3% for the 1200-mg dose to 77.4% for the 400-mg dose; Ascaris 50.3%
before and 0% afterwards.
aAfter two and four dewormings, eosinophil counts were significantly reduced for all the doses of albendazole, with respective P-values of <0.01 and <0.05.
bS.e.m., standard error of the mean.
cPrevalence of eosinophilia. The percentage of children with eosinophil counts exceeding the normal paediatric range for eosinophils in venous blood: 0.05 – 0.45 × 109/l.28,29 The mean prevalence in
the combined albendazole groups decreased from 57% before to 37% after deworming.
dAlbendazole per os, as Zentel® 400 mg tablets, SmithKline Beecham: treatment intervals approximately four months, compliance observed.
eChildren in this negative control group were treated with placebo only. They had no worms when the study began, but infections developed progressively, which probably explains the increases in
eosinophil counts and prevalence of eosinophilia.
Table 2. Changes in mean eosinophil counts and prevalence of eosinophilia in children: whole-school deworming programme (worm prevalence before and after
deworming is summarized in the first footnote).
Occasion Means (s.e.m.)a P-values of changes Prevalence of Number of children
in mean counts eosinophiliab
Before c 0.612 (0.032) – 47 200
After 2 d 0.437 (0.032) <0.01d 35 174
After 4 d 0.377 (0.031) <0.05d 23 197
After 6 d 0.346 (0.029) 0.08d 24 256
Worm prevalence before and after deworming with mebendazole: Trichuris 72% and 14%; Ascaris 19% and 0%.
aS.e.m., standard error of the mean.
bPercentage of children with counts exceeding the normal paediatric range for eosinophils in venous blood: 0.05–0.45 × 109/l.28,29
c
 = mebendazole 500 mg tablets (Vermox®, Janssen-Cilag): treatment intervals approximately four months. One tablet per os, compliance observed.
dReduction in eosinophil counts was significant (P < 0.05) after both two and four dewormings.  Further reduction after six dewormings approached significance.
influenced by the intervention. According to international crite-
ria,30 mebendazole at the 500 mg stat dose was highly effective
against Ascaris in terms of cure rates and egg reduction rates and
was moderately effective against Trichuris (data not shown).
Discussion
The children in both studies were infected by Trichuris and/or
Ascaris, and no eggs of other helminths were detected in faecal
samples that were obtained between four and six times from
each child. Trichuris larvae and a permanently embedded
portion of the adult worm are in prolonged contact with
lymphoid tissue, mast cells and eosinophils in the intestinal
mucosa.13 Ascaris larvae undergo extensive tissue migration but
adult worms probably have less direct contact with eosinophils.
Investigations concerning immune responses in endemic
trichuriasis and ascariasis have reported on various immunolog-
ical variables7–12,24 but not on eosinophilia per se. Human
trichuriasis seems to be associated with a mixed T-helper cell
type 1 (Th1) and Th2 immune response,12,13,24 while ascariasis is
associated with Th2 polarization of the cytokine profile, which
may be re-balanced by deworming.7–9,11 Inappropriate Th2 bias
during ascariasis, and infestation by some other worms, appears
to be part of the reason for reduced efficacy of vaccines against
various diseases, including cholera and tuberculosis.5–26 The
effectiveness of cholera and bacille Calmette-Guérin (BCG)
vaccines can be restored to some extent by anthelminthic treat-
ment.7,11,17,18,20,21
Activated eosinophils can attack stages of some helminths
within tissues by releasing molecules that are cytotoxic to
larvae.14 Research using mice suggests that this kind of damage
to larvae of Strongyloides stercoralis exposes antigens to which
there may be an additional T-cell-dependent immune
response.31 This might apply in other helminthic infections as
well. Immunoregulation by eosinophils can be via production of
functional interleukin-13, which is a Th2 cytokine.32
Worm infestation and atopy can occur together10,19,22,25 and
eosinophilia is characteristic of both conditions.10,15 The question
of whether atopic disorders might be suppressed or exacerbated
by anthelminthic treatment, in the presence of aeroallergens
and sometimes genetic predisposition as well, has not yet been
resolved. The relationship might vary with high and low
endemicity of worm infestation, resulting in continuous or
intermittent contact with helminthic antigens.10,19,22,25
Reversal of eosinophilia, which implies a degree of suppres-
sion of humoral immunity, was sustained in both studies at the
whole-school level by means of regular treatment with
benzimidazole anthelminthics. This result indicates that possi-
ble changes in other immune response markers should be re-
searched, as well as the consequences of deworming in relation
to co-endemic diseases. For immunological reasons in particular,
deworming programmes could be relevant to the success of
school and pre-school vaccination campaigns.5–26,31,32
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